GCG and metabolic dysfunction-associated steatohepatitis: The glucagon like peptide 1 (GLP1) based agent, Semaglutide is another anti-diabetic drug with promising result in clinical trials for NASH (Flint et al., 2021; Newsome et al., 2021).